Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

The Use of Extracellular Vesicles as a Promising Therapeutic Approach for Pulmonary Diseases

Chaleshtori SS., Pirkani Z., Fakhr MJ., Mokhber M.

Laboratory Study on Immune Modulation, published in Health Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Health Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40503352
PMCID
PMC12152770
DOI
10.1002/hsr2.70853
Citations
1

Abstract (original English)

Background and aims Pulmonary disorders significantly impact worldwide healthcare, highlighting the necessity for enhanced diagnostic and treatment approaches. This narrative review seeks to investigate the potential of extracellular vesicles (EVs) as an innovative therapeutic strategy for diverse pulmonary disorders. Methods This review synthesizes existing data about the function of extracellular vesicles (EVs) in pulmonary health and pathology, emphasizing their modes of action, including the transfer of proteins, nucleic acids, and lipids for intercellular communication. It also examines the implications of EVs in targeted medication delivery, immunomodulation, and tissue regeneration. Results EVs, including microvesicles and exosomes, have demonstrated promise in treating respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Additionally, EVs may serve as valuable biomarkers for early disease detection, prognosis, and monitoring. However, challenges remain regarding the standardization of EV isolation methods and characterization protocols to ensure safety and clinical applicability. Conclusion In summary, extracellular vesicles hold potential for transforming the management of pulmonary diseases by providing insights into pathophysiology, enabling early diagnosis, and facilita

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research